Application of ethyl lauroylarginate as feed additive

A technology of use and feed, applied in the field of use of lauroyl arginine ethyl ester as a feed additive, can solve the problems of unresearched LAE's independent bacteriostatic effect and uninstructed, and reduce the risk of infection with Riemerella anatipestifer , small toxic side effects, no effect on survival

Inactive Publication Date: 2018-11-16
EAST CHINA NORMAL UNIV
View PDF15 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this method involves multiple antibacterial components including LAE, and the antibacterial effect of LAE alone was not studied
At the same time, the invention only teaches that the composition is used for daily products, cleaning agents, wound care compositions, various foods, various medical cleaning products, etc., and does not teach how to use a single LAE component for poultry Use of antibacterial feed for aquatic products

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ethyl lauroylarginate as feed additive
  • Application of ethyl lauroylarginate as feed additive
  • Application of ethyl lauroylarginate as feed additive

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Embodiment one: micro-broth dilution method measures LAE to bacterium minimum inhibitory concentration (MIC)

[0057] Principle and purpose: According to the micro-broth dilution method stipulated by CLSI, after co-incubating the drug and bacteria in a 96-well plate for 24 hours, the minimum drug concentration at which bacterial growth is inhibited is the minimum inhibitory concentration of the drug.

[0058] Methods: LAE and bacteria (the clinical isolate of Riemerella anatipestifer RA‐11, Staphylococcus aureus ATCC 29213, and Escherichia coli ATCC 25922) were diluted with tryptone soy broth (TSB) and cultured. Added to the 96-well plate, and set up blank control medium CK1 without bacteria, medium CK2 added with LAE (1000 μg / ml) and control medium CK3 without drug LAE but containing normal growth of bacteria. The 96-well plate was incubated in a 37 °C incubator for 24 h, and then the absorbance value at 625 nm of each well was measured. OD of blank control medium CK1...

Embodiment 2

[0063] Embodiment two: LAE is to the mensuration of effective bactericidal time of bacteria

[0064] Principle and purpose: Drugs and bacteria are co-incubated, and a part of the samples are taken out at regular intervals for bacterial plate counting, so as to obtain the growth curve of the bacteria under the action of the drug, which is the time-killing curve of the drug.

[0065] Method: The bacteria in the logarithmic phase were mixed with different concentrations of LAE solutions, samples were taken at 0, 0.5, 1, 1.5, and 2 hours after the addition of the drug, and the 10-fold serial dilution points were placed on the TSA plate, and cultured at 37°C for 18‐ 24h. Calculate the bacterial concentration of each dosing group at each time point by the number of colonies, and draw as follows figure 1 Bacterial survival curves are shown.

[0066] Result analysis: at a concentration of 16 μg / ml, LAE can completely kill Riemerella anatipestifer and Escherichia coli within 30 minu...

Embodiment 3

[0067] Example 3: LAE-induced bacterial drug resistance experiment

[0068] Principle and purpose: Bacteria can be induced to produce drug-resistant bacteria at sub-inhibitory concentrations, and the drug-induced bacteria can be detected by long-term transfer of bacteria cultured with sub-inhibitory concentrations of drugs to fresh drug-containing media Ability to generate resistance mutations.

[0069] Method: The bacteria in the logarithmic phase were mixed with the LAE solution in a glass test tube, sealed with a cotton plug, and placed in a constant temperature shaker at 37°C and 220 rpm for 24 hours. Afterwards, check the MIC of the drug every 24 hours, and add the bacterial solution with the highest drug concentration (that is, the highest drug concentration lower than the MIC) that can cultivate a turbid bacterial solution to fresh cultures containing different drug concentrations at a ratio of 1:100. In Kiri, culture at 37°C, 220rpm for 24h and last for 30 days. Chlo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel feed additive. The feed additive is an antibacterial agent containing a condensation compound derived from fatty acid and esterified binary amino acids and has the advantages that riemerella anatipestifer, RA diseases of ducklings caused by riemerella anatipestifer, RA can be prevented and treated, peritonitis diseases caused by escherichia coli and staphylococcusaureus can be treated, and septicemia of fish caused by aeromonas sobria can be prevented and treated; bacteria can be effectively inhibited or killed, the risk that poultry, livestock and aquatic animals are infected with the bacteria can be greatly reduced, and the survival rate of the animals infected with pathogenic bacteria can be increased; and ethyl lauroylarginate can be safely degraded ina human body and an animal body and is small in toxic and side effects, so that the generation of environmental drug-resistant bacteria caused by the fact that residual antibacterial agents are discharged into the environment can be avoided, and the negative influence on the environment is less while the effective antibacterial effect is achieved.

Description

[0001] This application requires Chinese invention patent application 201711071008.7, the invention name is "Ethyl Lauroyl Arginate and its derivatives as feed additives” priority application. technical field [0002] The invention relates to the application of the compound lauroyl arginine ethyl ester in the preparation of veterinary antibacterial agents, feed additives or feed nutrition energy substances. Background technique [0003] Riemerella anatipestifer is a contagious disease caused by Riemerella anatipestifer (RA), also known as duck infectious serositis, duck septicemia, duck plague syndrome, and duck plague. bacillosis etc. It is more common in ducklings aged 1-8 weeks, and ducklings aged 2-4 weeks are most susceptible. It is acute or chronic sepsis, clinically manifested as increased eye and nasal secretions, panting, coughing, diarrhea, ataxia, and head and neck tremors, and a small number of chronic cases have symptoms such as head and neck skewing. The l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/223A61P31/04A23K50/75A23K50/30A23K50/10A23K50/20A23K50/40A23K50/80A23K20/142
CPCA23K20/142A23K50/10A23K50/20A23K50/30A23K50/40A23K50/75A23K50/80A61K31/223Y02A40/70
Inventor 易正芳邵婷范婷婷刘明耀
Owner EAST CHINA NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap